TY - JOUR
T1 - Sonopermeation to improve drug delivery to tumors
T2 - from fundamental understanding to clinical translation
AU - Snipstad, Sofie
AU - Sulheim, Einar
AU - de Lange Davies, Catharina
AU - Moonen, Chrit
AU - Storm, Gert
AU - Kiessling, Fabian
AU - Schmid, Ruth
AU - Lammers, Twan
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Introduction: Ultrasound in combination with microbubbles can make cells and tissues more accessible for drugs, thereby achieving improved therapeutic outcomes. In this review, we introduce the term ‘sonopermeation’, covering mechanisms such as pore formation (traditional sonoporation), as well as the opening of intercellular junctions, stimulated endocytosis/transcytosis, improved blood vessel perfusion and changes in the (tumor) microenvironment. Sonopermeation has gained a lot of interest in recent years, especially for delivering drugs through the otherwise impermeable blood-brain barrier, but also to tumors. Areas covered: In this review, we summarize various in vitro assays and in vivo setups that have been employed to unravel the fundamental mechanisms involved in ultrasound-enhanced drug delivery, as well as clinical trials that are ongoing in patients with brain, pancreatic, liver and breast cancer. We summarize the basic principles of sonopermeation, describe recent findings obtained in (pre-) clinical trials, and discuss future directions. Expert Opinion: We suggest that an improved mechanistic understanding, and microbubbles and ultrasound equipment specialized for drug delivery (and not for imaging) are key aspects to create more effective treatment regimens by sonopermeation. Real-time feedback and tools to predict therapeutic outcome and which tumors/patients will benefit from sonopermeation-based interventions will be important to promote clinical translation.
AB - Introduction: Ultrasound in combination with microbubbles can make cells and tissues more accessible for drugs, thereby achieving improved therapeutic outcomes. In this review, we introduce the term ‘sonopermeation’, covering mechanisms such as pore formation (traditional sonoporation), as well as the opening of intercellular junctions, stimulated endocytosis/transcytosis, improved blood vessel perfusion and changes in the (tumor) microenvironment. Sonopermeation has gained a lot of interest in recent years, especially for delivering drugs through the otherwise impermeable blood-brain barrier, but also to tumors. Areas covered: In this review, we summarize various in vitro assays and in vivo setups that have been employed to unravel the fundamental mechanisms involved in ultrasound-enhanced drug delivery, as well as clinical trials that are ongoing in patients with brain, pancreatic, liver and breast cancer. We summarize the basic principles of sonopermeation, describe recent findings obtained in (pre-) clinical trials, and discuss future directions. Expert Opinion: We suggest that an improved mechanistic understanding, and microbubbles and ultrasound equipment specialized for drug delivery (and not for imaging) are key aspects to create more effective treatment regimens by sonopermeation. Real-time feedback and tools to predict therapeutic outcome and which tumors/patients will benefit from sonopermeation-based interventions will be important to promote clinical translation.
KW - blood-brain barrier
KW - cancer
KW - drug delivery
KW - drug targeting
KW - microbubbles
KW - nanomedicine
KW - Sonopermeation
KW - sonoporation
KW - ultrasound
KW - 22/4 OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85058671633&partnerID=8YFLogxK
U2 - 10.1080/17425247.2018.1547279
DO - 10.1080/17425247.2018.1547279
M3 - Review article
C2 - 30415585
AN - SCOPUS:85058671633
SN - 1742-5247
VL - 15
SP - 1249
EP - 1261
JO - Expert opinion on drug delivery
JF - Expert opinion on drug delivery
IS - 12
ER -